Bli medlem
Bli medlem

Du är här


A1M: A1M Pharma initiates research collaboration with global leader CSL Behring for combination treatment with A1M and plasma proteins

A1M Pharma has initiated a research collaboration with global
biotherapeutics company CSL Behring to investigate the potential for
combining Alpha 1 Microglobulin (A1M) with proteins extracted from
the fractionation of human plasma such as hemopexin and haptoglobin.
This collaboration strengthens A1M Pharma's position in the use of
A1M for the treatment of life-threatening diseases with therapies
that are based on naturally occurring substances.

Many proteins in the human body contribute to immunoprotection against
disease processes. Their different activities often act together to
address the complex biochemical processes that occur in connection
with damage to tissues and infection. When red blood cells are broken
open by injury or disease, the body's defenses operate at different
levels and in different pathways to clear up the "spillage" of these
cells' contents, especially hemoglobin and its by-products when it
breaks down in the blood releasing reactive oxygen species (ROS).
These compounds can penetrate and damage the tissues of organs such
as the kidneys, and are what causes serious conditions such as
pre-eclampsia and acute kidney injury.

The endogenous protein A1M is thought to provide many of the
protective mechanisms in bodily tissues while hemopexin and
haptoglobin are mainly active in the circulating blood. This means
that it may be possible to combine these substances to potentially
achieve additional therapeutic benefits by developing combination
treatments. The objective of the research collaboration is to
investigate these possibilities.

The research program under the collaboration will be a joint endeavor,
with each company carrying its own costs. For A1M Pharma's part, the
cost of the collaboration lies within the existing research budget
for modes of action of A1M as it affects pre-eclampsia and related
conditions. This means that the collaboration strengthens A1M
Pharma's intensive research program for patients suffering from
kidney related diseases and also directly supports A1M Pharma's
progress in drug development.

"We look forward to partnering with A1M Pharma to advance the current
science in this important yet complex area," said Andrew Nash, CSL's
Senior Vice President of Research. "We are truly excited about the
potential of these combined proteins and are eager to explore the
differential actions of our proteins, haptoglobin and hemopexin, in
combination with A1M."

A1M Pharma's Development Manager Eddie Thordarson welcomes the
collaboration with CSL Behring, a global biotherapeutics leader and
one of the world's largest manufacturers of drugs based on plasma

"The collaboration with CSL Behring lends support to our research
program in naturally occurring proteins that form the basis for
effective treatments for important indications. The collaboration
with CSL Behring's experienced and respected industry research group
provides us with important insight into dosing and delivery of
therapeutic proteins," commented A1M Pharma's Development Manager
Eddie Thordarson.

For more information, please contact:
Tomas Eriksson, VD
Tel: +46 (0)46 286 50 30

About A1M Pharma
A1M Pharma develops a diagnostic method and treatment for
pre-eclampsia, a condition that affects around 10 million pregnant
women worldwide each year. This disorder is responsible for 76,000
maternal and 500,000 infant deaths each year and it is the cause of
15 % of all premature births. Currently, there is no effective
diagnostic method or curative treatment for impaired kidney function
associated with pre-eclampsia. The only option is therefore to
terminate pregnancy by inducing delivery which leads to premature
infants and substantial health care costs. Several studies indicate
that A1M Pharma's candidate drug, the protein A1M
(alpha-1-microglobulin), restores the impaired kidney function by
repairing damaged tissue and protect against oxidative stress. New
findings indicate that the cells within the heart are protected in a
similar way. Apart from the connection with pre-eclampsia, kidney
injury is a condition often accompanying major surgery and
transplantation and the company is therefore also developing a
treatment for the closely related indication acute kidney injury.
Acute kidney injury that can lead to permanent kidney damage affects
12 million people every year.


Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.